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is vital for population health to survive.
Reimbursement promoting new healthcare
delivery models and social programs that
reward health outcomes rather than the
volume of services are the cornerstone of
this model. She emphasized that the Triple
Aim is inextricably linked to value.

“Population health will absolutely need to
have longevity…population health is a business
imperative and longevity is one of the best
outcomes,” explained Dr. Susan Freeman
as she began her Forum presentation. Dr.
Freeman is the founding CEO and President
of Temple Center for Population Health,
LLC. She is also the Chief Medical Officer,
Temple University Health System, Vice Dean of
Health Care Systems and Professor of Clinical
Medicine at the Lewis Katz School of Medicine
at Temple University.

Dr. Freeman spent some time talking about
the longevity of value. The impact of ACA
has been critical in bringing to life the shift
from volume to value. The components
of ACA (such as shared savings, valuebased purchasing, readmissions reduction
programs, ACOs, health insurance
exchanges and Medicaid expansion) have
been important to the longevity. Freeman
explained that ACA created new pathways
for connecting people to coverage and
she described the impressive numbers of
enrollees for Medicare, Medicaid, SCHIP and
the Basic Health Program. She emphasized
the importance of the role of CMS and the
CMS Innovation Center, particularly as it
relates to the success of ACA.

Dr. Freeman explored how the definition
of population health is really very complex
and, in her expanded view, longevity is a
key component. The conceptual framework
that she shared involves tackling large-scale
social, economic, and environmental issues
in a way that changes outcomes. Within
this framework, it is important to examine
why some populations are healthier than
others while at the same time including
policy development, academic agenda and
resource allocation in the equation.
Dr. Freeman organized her talk into different
themes and started out by sharing a
framework of population health as a clinical
and business model – a model she states

Despite the successes of ACA, Freeman doesn’t
feel that the Triple Aim has been fully achieved.
Issues of disease burden, socioeconomic
factors and social determinants of health,
legacy systems, and interoperability are major
challenges. She went on to describe data
related to disease burden in Philadelphia,
which includes high percentages of obesity,
smoking, sexually transmitted infections,
opioid related mortalities, and persons living
below the poverty level.

Dr. Freeman then provided an overview
of Temple Health and Temple Center for
Population Health (TCPH). The goal of
TCPH is to attain a sustainable, coordinated
model of health care delivery through
clinical and business integration, community
engagement, and a balance of medical and
nonmedical interventions to promote high
value care and healthy populations. The
immediate focus has been on low-acuity
admissions, high utilizers, post-acute care,
ambulatory sensitive conditions, predictive
analytics, and balancing the revenue cycle
against the value proposition. As part of the
overall structure, there is a strong emphasis
on primary care, investment in infrastructure,
value-based contracts, care transitions, and
care reaching into the community using
community health workers.
Dr. Freeman summarized her talk by
discussing longevity, high-value healthcare,
and the future. She does believe that the
insurance market is likely to change and that
Medicare may shift to all “Advantage” and
Medicaid may shift to block grants and more
control at the state level. She outlined various
initiatives and themes which may play a big
role in the longevity of population health such
as consumerism, collaboration, academic
mission, Healthy People 2030, Public Health
3.0 and ongoing efforts to improve access
and quality to decrease disparities. Particularly
important to the future is the 21st Century
Cures Act, which provides funding to various
research and healthcare initiatives including
the Cancer Moonshot.

